文献速递新药、器械与细胞基因治疗研发基础与转化研究

双功能载脂蛋白C-II模拟/载脂蛋白C-III拮抗肽D6PV降低血浆甘油三酯

A dual apolipoprotein C-II mimetic-apolipoprotein C-III antagonist peptide lowers plasma triglycerides.
PubMed 文献 · Sci Transl Med · 2020-01-01

研究设计了一种名为D6PV的载脂蛋白C-II模拟肽,可激活脂蛋白脂肪酶并拮抗载脂蛋白C-III的升甘油三酯效应。在载脂蛋白C-II缺陷小鼠和hAPOC3转基因小鼠中,D6PV数小时内使甘油三酯降低超过80%;在非人灵长类中皮下生物利用度约80%,半衰期42至50小时。

要点

  • D6PV在hAPOC3转基因小鼠中数小时内降低甘油三酯超过80%。
  • D6PV在非人灵长类中皮下生物利用度约80%,半衰期42至50小时。
  • D6PV在诱导性Lpl敲除小鼠中降低甘油三酯50%,提示可独立于LPL发挥作用。

核心结论

  • D6PV通过作为载脂蛋白C-II模拟物和载脂蛋白C-III拮抗剂降低血浆甘油三酯,显示治疗高甘油三酯血症的潜力。

研究设计与样本

  • 基于全原子分子动力学模拟、结构预测程序和生物物理技术设计D6PV肽。
  • 在人类高甘油三酯血浆中离体评估D6PV激活脂蛋白脂肪酶的效力。
  • 在载脂蛋白C-II缺陷小鼠、hAPOC3转基因小鼠、hAPOC3-Tg×Ldlr-/-小鼠和诱导性Lpl敲除小鼠中评估疗效。
  • 在非人灵长类中评估皮下生物利用度和终末半衰期。

主要发现

  • D6PV在人类高甘油三酯血浆中激活脂蛋白脂肪酶的效力强于全长载脂蛋白C-II。
  • 在载脂蛋白C-II缺陷小鼠和hAPOC3转基因小鼠中,D6PV数小时内使甘油三酯降低超过80%。
  • 在hAPOC3转基因小鼠中,D6PV使血浆载脂蛋白C-III降低80%、载脂蛋白B降低65%。
  • 在hAPOC3-Tg×Ldlr-/-小鼠中,D6PV治疗使LDL胆固醇降低10%而非蓄积。
  • 在诱导性Lpl敲除小鼠中,D6PV使甘油三酯降低50%,证实可独立于LPL发挥作用。

临床怎么用

  • D6PV作为双功能肽可同时激活LPL和拮抗apoC-III,为高甘油三酯血症提供新治疗策略。
  • D6PV与高密度脂蛋白结合延长半衰期,支持皮下给药并可能减少给药频率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recent genetic studies have established that hypertriglyceridemia (HTG) is causally related to cardiovascular disease, making it an active area for drug development. We describe a strategy for lowering triglycerides (TGs) with an apolipoprotein C-II (apoC-II) mimetic peptide called D6PV that activates lipoprotein lipase (LPL), the main plasma TG-hydrolyzing enzyme, and antagonizes the TG-raising effect of apoC-III. The design of D6PV was motivated by a combination of all-atom molecular dynamics simulation of apoC-II on the Anton 2 supercomputer, structural prediction programs, and biophysical techniques. Efficacy of D6PV was assessed ex vivo in human HTG plasma and was found to be more potent than full-length apoC-II in activating LPL. D6PV markedly lowered TG by more than 80% within a few hours in both apoC-II-deficient mice and hAPOC3-transgenic (Tg) mice. In hAPOC3-Tg mice, D6PV treatment reduced plasma apoC-III by 80% and apoB by 65%. Furthermore, low-density lipoprotein (LDL) cholesterol did not accumulate but rather was decreased by 10% when hAPOC3-Tg mice lacking the LDL-receptor (hAPOC3-Tg × Ldlr-/- ) were treated with the peptide. D6PV lowered TG by 50% in whole-body inducible Lpl knockout (iLpl-/- ) mice, confirming that it can also act independently of LPL. D6PV displayed good subcutaneous bioavailability of about 80% in nonhuman primates. Because it binds to high-density lipoproteins, which serve as a long-term reservoir, it also has an extended terminal half-life (42 to 50 hours) in nonhuman primates. In summary, D6PV decreases plasma TG by acting as a dual apoC-II mimetic and apoC-III antagonist, thereby demonstrating its potential as a treatment for HTG.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Wolska A, Lo L, Sviridov DO, et al. A dual apolipoprotein C-II mimetic-apolipoprotein C-III antagonist peptide lowers plasma triglycerides. Sci Transl Med. 2020. PMID: 31996466. doi:10.1126/scitranslmed.aaw7905

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。